ResMed's stock is near a 52-week low despite experiencing 21% earnings per share growth. The decline may be related to concerns over GLP-1 data, although the nature of these concerns is unclear. ResMed's stock has fallen significantly, with some outlets suggesting it may be a buying opportunity, while others see it as a warning sign.